SavedAdd your journal

Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2017 / Cilt: 26 - Sayı: 3

New Immunosuppressive Drugs Used in Renal Transplantation

Böbrek Naklinde Kullanılan Yeni İmmünsupresif İlaçlar

Özkan GÜNGÖR
Bülent TOKGÖZ
İrem PEMBEGÜL
Alper ALP
Pages
239–245
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we intended to summarize the new immunosuppressive drugs that have entered use in recent years.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Renal transplantation is the most prominent treatment of end-stage renal failure.
📊
Key Findings & Data:Unfortunately, acute and chronic rejections and drug toxicities reduce graft survival in the post-transplantation period.
💡
Conclusion & Impact:In this review, we intended to summarize the new immunosuppressive drugs that have entered use in recent years.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Renal transplantation is the most prominent treatment of end-stage renal failure. Unfortunately, acute and chronic rejections and drug toxicities reduce graft survival in the post-transplantation period. An attempt has therefore been made in recent years to develop new drugs that can reduce rejections and drug toxicities. In this review, we intended to summarize the new immunosuppressive drugs that have entered use in recent years.

Özet

Son dönem böbrek yetmezliğinin en seçkin tedavi yöntemi böbrek naklidir. Ne yazıkki akut- kronik rejeksiyonlar ve ilaç toksisiteleri nakil sonrası dönemde organ sağ kalımını kısaltmaktadır. Bu yüzden son yıllarda rejeksiyonları ve ilaç toksisitelerini azaltabilecek yeni ilaçların bulunması amaçlanmıştır. Biz bu derlemede son yıllarda böbrek naklinde kullanıma girmiş yeni immünsupresif ilaçların başlıcalarını özetlemeyi amaçladık.

🔖

Cite This Article

GÜNGÖR, Ö., TOKGÖZ, B., PEMBEGÜL, İ., ALP, A. (2022). New Immunosuppressive Drugs Used in Renal Transplantation. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 26 - Sayı: 3, 239–245. https://ajindex.com/articles/636138

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Webber A, Hirose R, Vincenti F: Novel strategies in immunosuppression: Issues in perspective. Transplantation 2011
  2. 1064 2. Hadaya K, Ferrari-Lacraz S, Fumeaux D, Boehlen F, Toso C, Moll S, Martin PY, Villard J: Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 2011
  3. 2527 3. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM: Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011
  4. 2413 4. Soliris® (eculizumab), Alexion Prescribing Information. (http:// alexionpharma. com/Documents/soliris_pi-4-2014.aspx) 5. Zaza G, Tomei P, Granata S, Boschiero L, Lupo A: Monoclonal antibody therapy and renal transplantation: Focus on adverse effects. Toxins (Basel) 2014
  5. 891 6. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, DragonDurey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C: Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013
  6. 562 7. Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, King KE, Kraus E, Lees LM, Melancon JK, Stewart ZA, Warren DS, Zachary AA, Montgomery RA. The use of antibody to complement protein C5 for salvage treatment of severe antibodymediated rejection. Am J Transplant 2009
  7. 235 8. González-Roncero F, Suñer M, Bernal G, Cabello V, Toro M, Pereira P, Angel Gentil M: Eculizumab treatment of acute antibodymediated rejection in renal transplantation: Case reports. Transplant Proc 2012
  8. 2694 9. Stewart ZA, Collins TE, Schlueter AJ, Raife TI, Holanda DG, Nair R, Reed AI, Thomas CP: Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc 2012
  9. 3036 10. Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, GaronzikWang JM, Van Arendonk KJ, Gupta N, Lonze BE, Alachkar N, Kraus ES, Desai NM, Locke JE, Racusen LC, Segev DL, Montgomery RA: Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 2014
  10. 863 11. Cornell LD, Schinstock CA, Gandhi MJ, Kremers WK, Stegall MD: Positive crossmatch kidney transplant recipients treated with eculizumab: Outcomes beyond 1 year. Am